Literature DB >> 15674352

Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling.

Viqar Syed1, Kasturi Mukherjee, James Lyons-Weiler, Kin-Mang Lau, Tetsuo Mashima, Takashi Tsuruo, Shuk-mei Ho.   

Abstract

Although progesterone (P4) has been implicated to offer protection against ovarian cancer (OCa), little is known of its mechanism of action. The goal of this study was to identify P4-regulated genes that have anti-OCa action. Three immortalized nontumorigenic human ovarian surface epithelial (HOSE) cell lines and three OCa (OVCA) cell lines were subjected to 5 days of P4 treatment. Transcriptional profiling with a cDNA microarray containing approximately 2400 known genes was used to identify genes (1) whose expression was consistently downregulated in OVCA cell lines compared to HOSE cell lines, and (2) whose expression was restored in OCa cell lines by P4 treatment. From the candidates selected, activating transcription factor-3 (ATF-3), caveolin-1, deleted in liver cancer-1 (DLC-1), and nonmetastatic clone 23 (NM23-H2) were chosen for post hoc functional studies based on their previously reported action as tumor suppressors or apoptosis inducers. Semiquantitative RT-PCR analyses confirmed loss of or reduced transcription of these genes in OVCA cells when compared to HOSE cells and their upregulation following P4 treatment. Hormonal specificity was demonstrated by blockade experiments with a progestin antagonist RU 38486. Ectopic expression of caveolin-1, DLC-1, and NM23-H2 caused growth inhibition in OVCA cell cultures, but not in HOSE cell cultures, while forced expression of ATF-3 suppressed growth in both. Overexpression of AFT-3 also enhanced caspase-3 activity in both HOSE and OVCA cells, whereas ectopic expression of caveolin-1 and DLC-1 only activated this enzyme in OCa cells. In contrast, NM23-H2 overexpression was ineffective in activating caspase-3. Overexpression of any of the four genes in OCa cells reduced soft-agar colony formation and cell invasiveness. Taken together, we have identified four new P4-regulated, antitumor genes for OCa. However, their modes of action differ significantly; ATF-3 primarily functions as an apoptosis inducer, NM23-H2 as a suppressor of cell motility, and caveolin-1 and DLC-1 exhibiting features of classical tumor suppressors. To the best of our knowledge, except for NM23-H2, this is the first report linking P4 to the regulation of these tumor suppressor/proapoptotic genes, which could serve as future therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15674352     DOI: 10.1038/sj.onc.1207991

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

1.  Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.

Authors:  Anna E Maciag; Rahul S Nandurdikar; Sam Y Hong; Harinath Chakrapani; Bhalchandra Diwan; Nicole L Morris; Paul J Shami; Yih-Horng Shiao; Lucy M Anderson; Larry K Keefer; Joseph E Saavedra
Journal:  J Med Chem       Date:  2011-10-28       Impact factor: 7.446

2.  ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types.

Authors:  Anderly C Chüeh; Janson W T Tse; Michael Dickinson; Paul Ioannidis; Laura Jenkins; Lars Togel; BeeShin Tan; Ian Luk; Mercedes Davalos-Salas; Rebecca Nightingale; Matthew R Thompson; Bryan R G Williams; Guillaume Lessene; Erinna F Lee; Walter D Fairlie; Amardeep S Dhillon; John M Mariadason
Journal:  Clin Cancer Res       Date:  2017-06-13       Impact factor: 12.531

3.  Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events.

Authors:  Nathan J Charles; Peter Thomas; Carol A Lange
Journal:  Horm Cancer       Date:  2010-08       Impact factor: 3.869

4.  Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3.

Authors:  Carly St Germain; Nima Niknejad; Laurie Ma; Kyla Garbuio; Tsonwin Hai; Jim Dimitroulakos
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

5.  Mechanisms of non-metastatic 2 (NME2)-mediated control of metastasis across tumor types.

Authors:  Ram Krishna Thakur; Vinod Kumar Yadav; Pankaj Kumar; Shantanu Chowdhury
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-10       Impact factor: 3.000

6.  Patulin induces colorectal cancer cells apoptosis through EGR-1 dependent ATF3 up-regulation.

Authors:  Osong Kwon; Nak Kyun Soung; N R Thimmegowda; Sook Jung Jeong; Jae Hyuk Jang; Dong-Oh Moon; Jong Kyeong Chung; Kyung Sang Lee; Yong Tae Kwon; Raymond Leo Erikson; Jong Seog Ahn; Bo Yeon Kim
Journal:  Cell Signal       Date:  2011-12-30       Impact factor: 4.315

7.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

Review 8.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

Review 9.  ATF3 transcription factor and its emerging roles in immunity and cancer.

Authors:  Matthew R Thompson; Dakang Xu; Bryan R G Williams
Journal:  J Mol Med (Berl)       Date:  2009-08-25       Impact factor: 4.599

Review 10.  Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility.

Authors:  T Y Kim; D Vigil; C J Der; R L Juliano
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.